1. Home
  2. ZIM vs CELC Comparison

ZIM vs CELC Comparison

Compare ZIM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ZIM Integrated Shipping Services Ltd.

ZIM

ZIM Integrated Shipping Services Ltd.

N/A

Current Price

$29.75

Market Cap

3.5B

ML Signal

N/A

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$76.09

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ZIM
CELC
Founded
1945
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Marine Transportation
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
4.2B
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
ZIM
CELC
Price
$29.75
$76.09
Analyst Decision
Hold
Strong Buy
Analyst Count
4
13
Target Price
$28.30
★ $160.75
AVG Volume (30 Days)
★ 1.4M
703.8K
Earning Date
11-19-2026
11-11-2026
Dividend Yield
★ 4.06%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.94
N/A
Revenue Next Year
N/A
$979.15
P/E Ratio
$3.49
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.33
$45.15
52 Week High
$30.96
$151.02

Technical Indicators

Market Signals
Indicator
ZIM
CELC
Relative Strength Index (RSI) 52.00 37.33
Support Level $27.23 $77.84
Resistance Level $29.49 $96.39
Average True Range (ATR) 0.86 3.64
MACD -0.21 -0.37
Stochastic Oscillator 53.54 8.34

Price Performance

Historical Comparison
ZIM
CELC

About ZIM ZIM Integrated Shipping Services Ltd.

ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: